Navigation Links
Theratechnologies: TH9507 Phase 3 Clinical Update

/>
About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers or acquires innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is TH9507, now in Phase 3 clinical trials for a serious metabolic disorder known as HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

Forward-looking statements

This press release contains forward-looking statements regarding the conduct of the Company´s clinical program. By their very nature, these statements involve uncertainties and inherent risks, both general and specific, which give rise to the possibility that the predictions will not materialize. We therefore caution investors against placing undue reliance on these statements. We refer you to pages 16 - 18 of the 2006 Annual Report, which contain a more exhaustive analysis of the risks and uncertainties connected to the business of the Company. We have no obligation to update forward-looking statements and we do not undertake to do so.


Contacts:

Theratechnologies Inc.
Andrea Gilpin
Executive Director, IR & Communications
514-336-4804 x 205
agilpin@theratech.com

SOURCE: Theratechnologies inc.
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Theratechnologies Phase Clinical Update
(Date:8/28/2015)... The global mHealth market ... by 2020, growing at a CAGR of 47.6% from ... Grand View Research, Inc. Monitoring services is expected to ... to 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ... incidences of chronic diseases such as cancer, heart ailments, ...
(Date:8/27/2015)... 27, 2015 DURECT Corporation (Nasdaq: DRRX ... at three upcoming healthcare conferences.  , ... present at the Rodman & Renshaw Investment Conference on ... conference is being held at the St. Regis Hotel ... live audio webcast of the presentation will be available ...
(Date:8/27/2015)... India , August 27, 2015 According ... Product (Transfer, Hammock, Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, ... - Forecast to 2020", published by MarketsandMarkets, the Medical Lifting Sling ... USD 411.5 Million in 2015, at a CAGR of 11.4 % ... 136 ma rket data T ables and ...
Breaking Medicine Technology:mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5DURECT to Participate in Upcoming Healthcare Conferences 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... Pharmaceuticals, Inc. (Nasdaq: ALXA ), today announced that ... warrants to purchase shares of its common stock in an ... sole book-running manager in the offering. The ... no assurance as to whether or when the offering may ...
... Wash., Feb. 16, 2012  SCOLR Pharma, Inc. (OTCQB: SCLR) ... nutritional/vitamin products based on the Company,s patented oral drug delivery ... Eleven class-leading products are now being sold under various ... top retail chains.  Each product has ...
Cached Medicine Technology:Alexza Announces Proposed Public Offering of Common Stock and Warrants 2Alexza Announces Proposed Public Offering of Common Stock and Warrants 3Alexza Announces Proposed Public Offering of Common Stock and Warrants 4SCOLR Pharma, Inc. Launches Cutting Edge Nutritional Products at Major Retailers in 2012 2
(Date:8/29/2015)... ... 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted by ... will be devoting an entire short segment to the subject of diabetes. Diabetes is ... on a daily basis, but recent advancements in medical science may prove to be ...
(Date:8/28/2015)... ... 29, 2015 , ... Rio Salado College joined nine educational institutions ... part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded ... Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is designed to ...
(Date:8/28/2015)... ... , ... An online provider of CPAP machines, masks, supplies, and accessories, My ... affordable by offering shipping at no cost to you, directly to your door on ... size. My Cpap Store is located in Las Vegas, Nevada. , Sleep apnea is ...
(Date:8/28/2015)... , ... August 28, 2015 , ... The Kentucky State ... are qualified for the position they are applying for, they are unable to pass ... employers are considering altering drug testing policies in order to be able to hire ...
(Date:8/28/2015)... ... 2015 , ... With the goal of furthering music education programs in schools, ... Adams County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by ... in the underfunded school districts of Mendon and its neighboring town of Quincy, IL. ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
... The Jewish Home has named Nitin Nanda, M.D., ... Dr. Nanda will also serve as medical director of ... the Home,s Joyce Eisenberg-Keefer Medical Center on the Grancell ... positions, Dr. Nanda will be responsible for the supervision ...
... of Georgia is part of a large national study ... 10,000 healthy individuals in an effort to pinpoint variations ... samples taken from each group will enable a sophisticated ... convey individual risk for the disease that affects about ...
... Md., April 27 Patients with stone disease could ... University of California, San Francisco suggests that ... may be sufficient to inhibit the development of calcium ... Scientific Meeting of the American Urological Association (AUA). Increased ...
... nurses and doctors utilizing expert Geriatric Doctors, the Assistant Director of ... save the medical industry potentially, $200 Billion annually. , ... ... announces a tremendous saving in lives and medical costs of ...
... 27 Estill Medical Technologies, Inc., the industry leader ... the expansion of its Thermal Angel sales and marketing ... by quickly controlling core body temperature and infection risk. ... In emergency medicine, the golden hour refers to the ...
... drugstore.com , inc. (Nasdaq: DSCM ... and pharmacy products, today announced that they have reached ... sales and use taxes owed by the Company for ... )The Company has paid an aggregate of approximately $1.7 ...
Cached Medicine News:Health News:New Chief of Geriatric Psychiatry and Behavioral Health is Announced 2Health News:MCG participating in national study to identify genetic variants in schizophrenia 2Health News:MCG participating in national study to identify genetic variants in schizophrenia 3Health News:Drinking Diet Soda May Reduce the Risk of Forming Kidney Stones 2Health News:Medical Nurse Training, Inc. Announces New Techniques to Achieve Tremendous Savings of Lives and Medical Costs of Over $200 Billion Annually 2Health News:Thermal Angel Supports Infection Control During the Golden Hour 2Health News:drugstore.com, inc. Resolves New Jersey Sales and Use Tax Case 2
... designed with the proper sensitivity and specificity ... of autoimmune disease. Sera from over 2,000 ... individuals were tested during the development of ... compared the results to reference methods such ...
... functional human C1q coated in the solid phase ... stage, CIC in the diluted patient samples and ... into the C1q coated assay wells. After incubation, ... and a ready to use conjugate (goat anti-human ...
... are formed as a host defense against ... phagocytosis. If not cleared, CIC may be ... CIC are increased in Systemic Lupus Erythematosus ... involved in other autoimmune disorders as well ...
The K-ASSAY® D-Dimer Control set is intended to be used a consistent test sample of known concentration for monitoring the performance of D-Dimer immunoturbidimetric assays....
Medicine Products: